Zobrazeno 1 - 10 of 31 pro vyhledávání: '"Dominic W. Lai"'
5
First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors
Autor: Vivek Subbiah, Louie Naumovski, Hua Fang, Antoine Hollebecque, George D. Demetri, Chris Chen, Victor M. Villalobos, Jason J. Luke, Alexander I. Spira, Padmanee Sharma, Dominic W. Lai, James P. Allison, James W. Purcell, Anthony W. Tolcher, Randy Robinson, Akshanth R. Polepally, Huibin Yue, John D. Powderly
Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 27(13)
Purpose:Leucine-rich repeat containing 15 (LRRC15) is expressed on stromal fibroblasts in the tumor microenvironment of multiple solid tumor types and may represent an interesting target for therapy, particularly in patients with sarcomas where LRRC1
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7b06683d20ddbed17cd79560bf6e4f0
https://pubmed.ncbi.nlm.nih.gov/33820780
Zobrazit plný text záznamu
6
A phase I study to evaluate the safety and tolerability of AB680 combination therapy in participants with gastrointestinal malignancies
Autor: Jill Colabella, Eileen M. O'Reilly, Johanna C. Bendell, Wade Berry, Melissa Paoloni, William Grossman, Gulam Abbas Manji, Dominic W. Lai, Shubham Pant
Publikováno v: Journal of Clinical Oncology. 38:TPS788-TPS788
TPS788 Background: Metastatic pancreatic ductal adenocarcinoma (mPDAC) expresses very high levels of CD73 among tumor types, and CD73 expression level is a known poor prognostic factor in PDAC. Adenosine, a product of AMP breakdown by CD73, is highly
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5eda0d8ce971b14be699cfe40bc2c5db
https://doi.org/10.1200/jco.2020.38.4_suppl.tps788
Zobrazit plný text záznamu
7
Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors
Autor: David M. Hyman, Dominic W Lai, Efrat Dotan, Jennifer McDevitt, Matthew Joseph Gribbin, Denison Kuruvilla, Michael J. Birrer, Thomas Kaley, Vicky Makker, Lawrence Recht, Naiyer A. Rizvi, Mohammed M. Dar, Deborah K. Armstrong, Ronald B. Natale
Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 24(12)
Purpose: This first-in-human study aimed to determine the MTD and safety of MEDI3617, a selective anti–angiopoietin-2 (Ang2) mAb, alone and combined with bevacizumab or cytotoxic chemotherapy. Patients and Methods: This phase I/Ib, multicenter, ope
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c55c333c3f72411d38fe349ddd64c25c
https://pubmed.ncbi.nlm.nih.gov/29559563
Zobrazit plný text záznamu
8
Phase I evaluation of AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced malignancies
Autor: Daniel DiRenzo, Dominic W. Lai, P. de Souza, John D. Powderly, Alexander I. Spira, Joyson Joseph Karakunnel, Rodolfo Gutierrez, Aimee Rieger, Akshata Udyavar, J. Colabella
Publikováno v: Annals of Oncology. 30:v493
Background High levels of adenosine present in the tumor microenvironment have direct immunosuppressive impact on T-cell function and activation. AB928, a selective, small-molecule dual A2aR/A2bR antagonist, potently blocks the effects of adenosine a
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::12e2e338d717e41971e1047e3bebc0a0
https://doi.org/10.1093/annonc/mdz253.032
Zobrazit plný text záznamu
9
AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced tumors: Preliminary results from ongoing phase I studies
Autor: Joyson Joseph Karakunnel, Rodolfo Gutierrez, Dominic W. Lai, Wade Berry, Aimee Rieger, Matthew J. Walters, Arvind Chaudhry, Adam Park, Lisa Seitz, Paul de Souza, John D. Powderly, Devika Ashok, Lisa G. Horvath, Amanda Garofalo
Publikováno v: Journal of Clinical Oncology. 37:2604-2604
2604 Background: AB928, a selective, small-molecule A2aR/A2bR antagonist, potently blocks the immunosuppressive effects of high adenosine concentrations in the tumor microenvironment. Preclinically, combining adenosine receptor inhibition with either
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::522813153acadff3d9d59028ba85597c
https://doi.org/10.1200/jco.2019.37.15_suppl.2604
Zobrazit plný text záznamu
10
First-in-human phase 1 study of ABBV-085, an antibody-drug conjugate (ADC) targeting LRRC15, in sarcomas and other advanced solid tumors
Autor: Anthony W. Tolcher, Randy Robinson, Jason J. Luke, George D. Demetri, Vivek Subbiah, Scott Gulbranson, Victor M. Villalobos, Alexander I. Spira, Dominic W. Lai, Antoine Hollebecque, James W. Purcell, John D. Powderly, Melinda Myzak, Sreeneeranj Kasichayanula, Huibin Yue
Publikováno v: Journal of Clinical Oncology. 37:3004-3004
3004 Background: ABBV-085 is an ADC (conjugated to monomethyl auristatin E, drug:antibody ratio of 2:1) directed against leucine-rich repeat containing 15 (LRRC15), a type 1 transmembrane protein highly expressed on the surface of sarcomas and cancer
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1d65f0af3e279ce818303bb7ed86ea28
https://doi.org/10.1200/jco.2019.37.15_suppl.3004
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje